At Starling, we are developing the world's first continuous at-home urine remote monitoring platform which seamlessly integrates into any patients’ daily bathroom routine enabling passive screening for a large array of critical biomarkers. Using our automated toilet indwelling device and our connected AI driving our digital health infrastructure, our platform enables the early detection of our patient’s chronic health issues and the activation of downstream care workflows like never before. In the process, it can help prevent costly hospitalizations for health issues, including recurrent UTIs, diabetes, heart failure, kidney disease, at risk pregnancies, and many more. Our first product, UrinDx, is FDA registered and Medicare reimbursed for monitoring the risk of urinary tract infections and we have successfully launched with our first clinical partners. Our first enterprise customer that has a total potential contract value over $144M in ARR and we have the next 4 customers in our pipeline with plans to begin their pilots in 2024. Before expanding out to our broader $74B market in the US alone. Since Y-combinator (W22), we raised a 3.7M seed round led by some great institutional funds like Rebel Fund, Magic Fund and a strategic potential future acquirer.